Skip to content

Hip Denervation and Intra-articular Hydration in Damaged Hip in Axial Spondyloarthritis Patients

Hip Denervation and Intra-articular Hydration in Damaged Hip in Axial Spondyloarthritis Patients

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05219084
Enrollment
60
Registered
2022-02-01
Start date
2021-12-01
Completion date
2022-04-15
Last updated
2022-05-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age > 18, Patients With Axial SpA According to ASAS Criteria, Patients With Unilateral or Bilater Hip Damage According to BASRI Score

Brief summary

Background: The hip joint is frequently affected in axial spondyloarthritis (SpA) of adults with destructive effects in untreated patients. About 35% of axial SpA patients had either unilateral or bilateral hip arthritis. Destruction is more common with early-onset, active disease, or enthesitis. Objectives: The aim of this study is to evaluate the effect of hip denervation (HD) and intra-articular hydration (IAH) on pain, function score, hip mobility scores in a cohort of axial SpA patients with grade 3 and 4 hip BASRI scores.

Interventions

DRUGhip denervation

Lidocaine 2% 2ml was injected into each genicular nerve

DRUGintra-articular hydration

10 ml; of normal; saline were injected inside the hip joint

hip denervation and intra-articular hydration were conducted together

DRUGControl group

Normal; saline was injected subcutaneously

Sponsors

Suez Canal University
CollaboratorOTHER
Sohag University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* age 18 or more * Axial; SpA fulfilled ASA criteria * BASRI score grade 3 or 4 for one hip at least

Exclusion criteria

* patients younger than 18 * Axial; SpA with normal hip or hip involvement less than 3 on BASRI score

Design outcomes

Primary

MeasureTime frameDescription
Change in Harris functional hip scoreBaseline, after 4 weeks and after 12 weeksPain receives 44 points, function 47 points, range of motion 5 points, and deformity 4 points. Function is subdivided into activities of daily living (14 points) and gait (33 points). The higher the HHS, the less dysfunction. A total score of \<70 is considered a poor result; 70-80 is considered fair, 80-90 is good, and 90-100 is an excellent result
Change in visual analogue scaleBaseline , after 4 weeks and after 12 weeks0 means no pain, 100 means the highest degree of pain
Change in range of motion of the hipBaseline, after 4 weeks and after 12 weekship flexion, extension , internal; rotation , external; rotation , abduction , and adduction all were recopreded
Change in semiquantitative tenderness scoreBaseline, after 4 weeks and after 12 weeksa score from 0-3, 90 means no tenderness and 3 means maximum tenderness

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026